February 9, 2021 | Compliance An Analysis Of MHRA’s Latest Annual GMP Inspection Deficiencies Report Are you aware of recent changes from EMA pertaining to manufacturers of chemically synthesized drugs and biological products? Barbara Unger Principal Consultant 10 Minute Read
October 16, 2020 | Quality Addition of Biologics to Evaluation of Medicines for Potential Nitrosamine Contamination Barbara Unger Principal Consultant 1 Minute Read
May 7, 2020 | Compliance Avoiding and Reacting to Human Tissue, Cell and Gene Therapy Enforcement: Communication is Key Jerry Chapman Senior GMP Quality Expert, Govzilla 4 Minute Read
May 1, 2020 | Industry Updates Resuming Business Operations Following the COVID-19 Pandemic: Part Two Stephanie Colotti Senior Partner, Validant 8 Minute Read
April 20, 2020 | Industry Updates Resuming Business Operations Following the COVID-19 Pandemic: Part One Stephanie Colotti Senior Partner, Validant 8 Minute Read
January 4, 2020 | Quality The Eight Ways Nitrosamines Can Get in Your Product Barbara Unger Principal Consultant 9 Minute Read
October 25, 2019 | Compliance SPF Labeled Products are Drugs in the USA. Is Your Company Compliant Under FDA Regulations? John McShane Managing Partner, Validant 2 Minute Read
June 16, 2019 | Compliance EU MDR Applicable to Drug Delivery Systems Brian Burns CEO, Validant 1 Minute Read
February 16, 2019 | Compliance Outsourcing GxP Audits – Mindful Execution is Key to Success Barbara Unger Principal Consultant 4 Minute Read
December 16, 2018 | Compliance EU MDR/IVDR Compliance: A Road Map for Success Stephanie Colotti Senior Partner, Validant 1 Minute Read